Global CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025 – 2033

June 2025 | 180 pages | ID: G6E96373133FEN
DPI Research

US$ 4,000.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Global CAR T-Cell Therapy Market Size and Trends

The global chimeric antigen receptor (CAR) T-cell therapy market size was valued at USD 4.6 billion in 2024 and is projected to hit around USD 18.1 billion by 2033, growing at a CAGR of 14.6% during the forecast period 2025 to 2033.

Global CAR T-Cell Therapy Market Growth Drivers

Several factors contribute to the expansion of the global CAR T-cell therapy market. First and foremost, rising incidences of cancer have catalyzed the demand for effective treatment solutions. According to numerous studies, cancer rates are expected to escalate, prompting healthcare systems to explore and invest in advanced therapeutic options like CAR T-cell therapy.

In addition, the growing acceptance of personalized medicine has fostered an environment ripe for market growth. As more patients seek treatments tailored to their unique genetic profiles, CAR T-cell therapies have emerged as a favorable choice due to their personalization capabilities. Furthermore, ongoing clinical trials and research initiatives continue to demonstrate the effectiveness and versatility of CAR T-cell therapies, attracting significant investment from pharmaceutical companies.

Global CAR T-Cell Therapy Market Synopsis

This report presents an in-depth assessment of the global CAR T-cell therapy market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global CAR T-cell therapy market. The report also provides up-to-date historical market size data for the period 2021 – 2024 and an illustrative forecast to 2033 covering key market aspects like market value, share, analysis, and trends for the global CAR T-cell therapy market.

The report provides a detailed analysis of the current industry situation and market requirements, highlighting facts about the market size, market share, revenue for CAR T-cell therapy segments, and a vivid forecast to 2033.

It also provides a comprehensive analysis of the pricing landscape, policies and regulation, and reimbursement pattern by countries and therapy. The report also offers analysis and information according to categories such as market segments, application, technology, geographies, companies and competitive landscape. The report also provides a detailed description of the porter’s five forces analysis, SWOT analysis, funding, merger and acquisitions, pipeline, growth drivers and challenges of the global CAR T-cell therapy market.

The report concludes with the profiles of major market players in the global CAR T-cell therapy market. The key market players are evaluated on various parameters such as company overview, products/pipelines portfolio, company initiatives/news and recent sales revenue with forecast until 2033 of the global CAR T-cell therapy market.

The report will serve as a source for a 360-degree analysis in which various models will be thoroughly integrated. After a thorough study of the historical and current growth parameters, the growth prospects of the global CAR T-cell therapy market are determined with utmost precision.

Global CAR T-cell Market: Segmentation

CAR T-cell market is segmented on the basis of therapeutic application, targeted antigen, demographic, end user, product, company and geography.

Market Segment by Therapeutic Application
  • Multiple Myeloma
  • B-cell Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
Market Segment by Targeted Antigen
  • CD19
  • B-Cell Maturation Antigen (BCMA)
  • Market Segment by End User
  • Hospitals
  • Long-term Care Facilities
  • Specialty Centers
Market Segment by Demographic
  • Adults
  • Pediatrics
Market Segment by Therapies
  • Yescarta
  • Tecartus
  • Kymriah (Novartis)
  • Breyanzi
  • Abecma
  • Carvykti
  • Carteyva
Market Segment by Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
Market Segment by Company
  • Gilead Sciences
  • Novartis
  • Bristol Myers Squibb (BMS)
  • Legend Biotech (Johnson&Johnson)
  • JW (Cayman) Therapeutics Co Ltd
Key Features of the Report
  • The global CAR T-cell market provides granular level information about the market size, regional market share, historic market (2021-2024), and forecast (2025-2033)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
  • The report analyses the impact of the socio-political environment through SWOT analysis and competition through porter’s five force analysis
Key Questions the Report Addresses
  • What is the current scenario of the global CAR T-cell therapy market?
  • What is the total market size and forecast (until 2033) for the global CAR T-cell therapy market?
  • What will be the CAGR of the global CAR T-cell therapy market?
  • What are the major drivers of the global CAR T-cell therapy market?
  • What are the major challenges of the global CAR T-cell therapy market?
  • Which product segment dominates the global CAR T-cell therapy market?
  • Who are the prominent players operating in the global CAR T-cell therapy market?
  • Which region will lead the global CAR T-cell therapy market?
  • How will the industry evolve during the forecast period of 2025 – 2033?
1. MARKET DEFINITION

2. RESEARCH AND METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS – GLOBAL CAR-T CELL THERAPY MARKET

4.1 Growth Drivers
4.2 Challenges
4.3 Funding & M&A
4.4 Pipeline

5. CAR-T CELL THERAPY - MARKET OVERVIEW

6. GLOBAL CAR-T CELL THERAPY MARKET (2021 – 2033)

7. GLOBAL CAR-T CELL THERAPY MARKET SHARE ANALYSIS (2021 – 2033)

7.1 By Regions
7.2 By Therapeutic Application
7.3 By Targeted Antigen
7.4 By Demographic
7.5 By End User
7.6 By Product
7.7 By Company

8. BY REGIONS - GLOBAL CAR-T CELL THERAPY MARKET (2021 – 2033)

8.1 North America
  8.1.1 Market Size
  8.1.2 Growth Factors
  8.1.3 Approved CAR-T Cell Therapy
8.2 Europe
  8.2.1 Market Size
  8.2.2 Growth Factors
  8.2.3 Approved CAR-T Cell Therapy
8.3 Asia Pacific
  8.3.1 Market Size
  8.3.2 Growth Factors
  8.3.3 Approved CAR-T cell Therapy
8.4 Latin America
  8.4.1 Market Size
  8.4.2 Growth Factors
  8.4.3 Approved CAR-T Cell Therapy
8.5 Middle East
  8.5.1 Market size
  8.5.2 Growth Factors
  8.5.3 Approved CAR-T Cell Therapy
8.6 Africa
  8.6.1 Market Size
  8.6.2 Growth Factors
  8.6.3 Approved CAR-T Cell Therapy

9. BY THERAPEUTIC APPLICATION - GLOBAL CAR-T CELL THERAPY MARKET (2021 – 2033)

9.1 Multiple Myeloma
9.2 B-cell Lymphoma
9.3 Acute Lymphoblastic Leukemia (ALL)

10. BY TARGETED ANTIGEN - GLOBAL CAR-T CELL THERAPY MARKET (2021 – 2033)

10.1 CD19
10.2 B-Cell Maturation Antigen (BCMA)

11. BY DEMOGRAPHICS - GLOBAL CAR-T CELL THERAPY MARKET (2021 – 2033)

11.1 Adults
11.2 Pediatrics

12. BY END USERS - GLOBAL CAR-T CELL THERAPY MARKET (2021 – 2033)

12.1 Hospitals
12.2 Long-term Care Facilities
12.3 Specialty Centers

13. BY THERAPIES - GLOBAL CAR-T CELL THERAPY MARKET (2021 – 2033)

13.1 Yescarta
  13.1.1 Sales Revenue
  13.1.2 Key Factors Influencing Sales
  13.1.3 Yescarta Approvals: Country, Year & Indications
13.2 Tecartus
  13.2.1 Sales Revenue
  13.2.2 Key Factors Influencing Sales
  13.2.3 Tecartus Approvals: Country, Year & Indications
13.3 Kymriah (Novartis)
  13.3.1 Sales Revenue
  13.3.2 Key Factors Influencing Sales
  13.3.3 Kymriah Approvals: Country, Year & Treatment Indication
13.4 Breyanzi
  13.4.1 Sales Revenue
  13.4.2 Key Factors Influencing Sales
  13.4.3 Breyanzi Approvals: Country, Year & Treatment Indication
13.5 Abecma
  13.5.1 Sales Revenue
  13.5.2 Key Factors Influencing Sales
  13.5.3 Abecma Approvals: Country, Year & Treatment Indication
13.6 Carvykti
  13.6.1 Sales Revenue
  13.6.2 Key Factors Influencing Sales
  13.6.3 Carvykti Approvals: Country, Year & Treatment Indication
13.7 Carteyva
  13.7.1 Sales Revenue
  13.7.2 Key Factors Influencing Sales
  13.7.3 Carvykti Approvals: Country, Year & Treatment Indication
13.8 Others

14. PORTER’S FIVE FORCES ANALYSIS

14.1 Threat of New Entrants
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Threat of Substitute Products or Services
14.5 Intensity of Rivalry

15. SWOT ANALYSIS

15.1 Strengths
15.2 Weaknesses
15.3 Opportunities
15.4 Threats

16. PRICING LANDSCAPE - BY COUNTRY & THERAPY: GLOBAL CAR-T CELL THERAPY MARKET

16.1 United States
16.2 Europe (France, Germany, Italy, Spain, United Kingdom)
16.3 Asia-Pacific (Japan, China, India, Australia)
16.4 Middle East & Africa (Israel, Turkey)
16.5 Canada:
16.6 Factors Influencing the Overall Cost of CAR T-Cell Therapy
16.7 Future Pricing Trends

17. COUNTRY POLICIES & REGULATION: GLOBAL CAR-T CELL THERAPY MARKET

17.1 United States
17.2 European Union (EU)
17.3 United Kingdom (UK)
17.4 Japan
17.5 China
17.6 Australia
17.7 Common Policy & Regulatory Themes Across Countries

18. REIMBURSEMENT POLICIES – GLOBAL CAR-T CELL THERAPY

18.1 United States
18.2 Europe (EU5 - France, Germany, Italy, Spain, UK)
  18.2.1 France
  18.2.2 Germany
  18.2.3 Italy & Spain
  18.2.4 United Kingdom (UK)
18.3 Asia-Pacific (Japan, China, India, Australia)
  18.3.1 Japan
  18.3.2 China
  18.3.3 India
  18.3.4 Australia
18.4 Key Trends and Future Considerations

19. KEY PLAYERS ANALYSIS

19.1 Gilead Science
  19.1.1 Company Overview
  19.1.2 Products/Pipelines
  19.1.3 Company Initiatives/News
  19.1.4 Company CAR-T Cell Therapy Sales Revenue (2021 – 2033)
19.2 Novartis
  19.2.1 Company Overview
  19.2.2 Products/Pipelines
  19.2.3 Company Initiatives/News
  19.2.4 Company CAR-T Cell Therapy Sales Revenue (2021 – 2033)
19.3 Bristol Myers Squibb (BMS)
  19.3.1 Company Overview
  19.3.2 Products/Pipelines
  19.3.3 Company Initiatives/News
  19.3.4 Company CAR-T Cell Therapy Sales Revenue (2021 – 2033)
19.4 Legend Biotech (Johnson&Johnson)
  19.4.1 Company Overview
  19.4.2 Products/Pipelines
  19.4.3 Company Initiatives/News
  19.4.4 Company CAR-T Cell Therapy Sales Revenue (2022 – 2033)
19.5 JW (Cayman) Therapeutics Co Ltd
  19.5.1 Company Overview
  19.5.2 Products/Pipelines
  19.5.3 Company Initiatives/News
  19.5.4 Company CAR-T Cell Therapy Sales Revenue (2021 – 2033)
List of Figures
Figure 6-1: Global – CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 6-2: Global – Forecast for CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 7-1: Global – By Regions CAR-T Cell Therapy Market Share (Percent), 2021 – 2024
Figure 7-2: Global – Forecast for By Regions CAR-T Cell Therapy Market Share (Percent), 2025 – 2033
Figure 7-3: Global – By Therapeutic Application CAR-T Cell Therapy Market Share (Percent), 2021 – 2024
Figure 7-4: Global – Forecast for By Therapeutic Application CAR-T Cell Therapy Market Share (Percent), 2025 – 2033
Figure 7-5: Global – By Targeted Antigen CAR-T Cell Therapy Market Share (Percent), 2021 – 2024
Figure 7-6: Global – Forecast for Targeted Antigen CAR-T Cell Therapy Market Share (Percent), 2025 – 2033
Figure 7-7: Global – By Demographic CAR-T Cell Therapy Market Share (Percent), 2021 – 2024
Figure 7-8: Global – Forecast for By Demographic CAR-T Cell Therapy Market Share (Percent), 2025 – 2033
Figure 7-9: Global – By End User CAR-T Cell Therapy Market Share (Percent), 2021 – 2024
Figure 7-10: Global – Forecast for By End User CAR-T Cell Therapy Market Share (Percent), 2025 – 2033
Figure 8-1: North America – CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 8-2: North America – Forecast for CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 8-3: Europe – CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 8-4: Europe – Forecast for CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 8-5: Asia Pacific – CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 8-6: Asia Pacific – Forecast for CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 8-7: Latin America – CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 8-8: Latin America – Forecast for CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 8-9: Middle East – CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 8-10: Middle East – Forecast for CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 8-11: Africa – CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 8-12: Africa – Forecast for CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 9-1: Global - Multiple Myeloma CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 9-2: Global - Forecast for Multiple Myeloma CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 9-3: Global - B-cell Lymphoma CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 9-4: Global - Forecast for B-cell Lymphoma CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 9-5: Global - Acute Lymphoblastic Leukemia CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 9-6: Global - Forecast for Acute Lymphoblastic Leukemia CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 10-1: Global – CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 10-2: Global –Forecast for CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 10-3: Global – BCMA Antigen CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 10-4: Global – Forecast for BCMA Antigen CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 11-1: Global - Adults CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 11-2: Global - Forecast for Adults CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 11-3: Global - Pediatrics CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 11-4: Global - Forecast for Pediatrics CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 12-1: Global - Hospitals CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 12-2: Global - Forecast for Hospitals CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 12-3: Global - Long-term Care Facilities CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 12-4: Global - Forecast for Long-term Care Facilities CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 12-5: Global - Specialty Centers CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Figure 12-6: Global - Forecast for Specialty Centers CAR-T Cell Therapy Market (Million US$), 2025 – 2033
Figure 13-1: Global – Yescarta Sales Revenue (Million US$), 2021 – 2024
Figure 13-2: Global – Forecast for Yescarta Sales Revenue (Million US$), 2025 – 2033
Figure 13-3: Global – Tecartus Sales Revenue (Million US$), 2021 – 2024
Figure 13-4: Global – Forecast for Tecartus Sales Revenue (Million US$), 2025 – 2033
Figure 13-5: Global - Kymriah Sales Revenue (Million US$), 2021 – 2024
Figure 13-6: Global – Forecast for Kymriah Sales Revenue (Million US$), 2025 – 2033
Figure 13-7: Global - Breyanzi Sales Revenue (Million US$), 2021 – 2024
Figure 13-8: Global – Forecast for Breyanzi Sales Revenue (Million US$), 2025 – 2033
Figure 13-9: Global - Abecma Sales Revenue (Million US$), 2021 – 2024
Figure 13-10: Global – Forecast for Abecma Sales Revenue (Million US$), 2025 – 2033
Figure 13-11: Global - Carvykti Sales Revenue (Million US$), 2022 – 2024
Figure 13-12: Global – Forecast for Carvykti Sales Revenue (Million US$), 2025 – 2033
Figure 13-13: Global - Carteyva Sales Revenue (Million US$), 2021 – 2024
Figure 13-14: Forecast for Global - Carteyva Sales Revenue (Million US$), 2025 – 2033
Figure 13-15: Global - Other CAR-T Cell Therapy Sales Revenue (Million US$), 2023 – 2024
Figure 13-16: Global – Forecast for Other CAR-T Cell Therapy Sales Revenue (Million US$), 2025 – 2033
Figure 19-1: Gilead Science – Cell Therapy Pipeline Status, 2024
Figure 19-2: Gilead Science - Global CAR-T Cell Therapy Sales Revenue (Million US$), 2021 – 2024
Figure 19-3: Gilead Science – Forecast for Global CAR-T Cell Therapy Sales Revenue (Million US$), 2025 – 2033
Figure 19-4: Novartis – CAR-T Cell Therapy Pipeline Status, May 2025
Figure 19-5: Novartis - Global CAR-T Cell Therapy Sales Revenue (Million US$), 2021 – 2024
Figure 19-6: Novartis – Forecast for Global CAR-T Cell Therapy Sales Revenue (Million US$), 2025 – 2033
Figure 19-7: Bristol Myers Squibb (BMS)- Product Pipeline Status, May 2025
Figure 19-8: BMS - Global CAR-T Cell Therapy Sales Revenue (Million US$), 2021 – 2024
Figure 19-9: BMS – Forecast for Global CAR-T Cell Therapy Sales Revenue (Million US$), 2025 – 2033
Figure 19-10: Legend Biotech (Jhonson & Jhonson) – Product Pipeline Status, May 2025
Figure 19-11: Legend Biotech - Global CAR-T Cell Therapy Sales Revenue (Million US$), 2022 – 2024
Figure 19-12: Legend Biotech - Forecast for Global CAR-T Cell Therapy Sales Revenue (Million US$), 2025 – 2033
Figure 19-13: JW Therapeutics – Products Pipeline Status, May 2025
Figure 19-14: JW Therapeutics - Global CAR-T Cell Therapy Sales Revenue (Million US$), 2021 – 2024
Figure 19-15: JW Therapeutics – Forecast for Global CAR-T Cell Therapy Sales Revenue (Million US$), 2025 – 2033
List of Tables
Table 7-1: Global – By Product CAR-T Cell Therapy Market Share (Percent), 2021 – 2024
Table 7-2: Global – Forecast for By Product CAR-T Cell Therapy Market Share (Percent), 2025 – 2033
Table 7-3: Global – By Company CAR-T Cell Therapy Market (Million US$), 2021 – 2024
Table 7-4: Global – Forecast for By Company CAR-T Cell Therapy Market Share (Percent), 2025 – 2033


More Publications